Dermal fillers have historically been dominated by formulations based solely on Hyaluronic Acid. While these products provide effective volumisation and contouring, their limitations in tissue biointegration and regenerative capacity are well recognised. PRODERMIS PROSCULPT represents a paradigm shift: the world’s first hybrid filler to combine patented cross-linked Hyaluronic Acid with Polynucleotides in a single cohesive formulation.

This synergy does more than add two active ingredients together — it redefines the physical and biological behaviour of the filler within tissue.

‍

The Synergistic Mechanism: Structure + Regeneration

• Cross-linked Hyaluronic Acid remains the structural backbone, providing immediate volume restoration, projection, and lift. Through 4L™ Technology, the polymer network achieves superior elasticity, cohesiveness, and stability compared with conventional HA-only fillers.
• Polynucleotides are bioactive macromolecules with well-documented effects on fibroblast activation, collagen synthesis, tissue repair, and anti-inflammatory modulation. Their inclusion transforms PROSCULPT from a passive volumiser into a biologically active agent capable of promoting dermal regeneration.

When combined, the filler delivers not only correction of volume loss but also progressive improvement in dermal quality — an outcome not achievable by Hyaluronic Acid alone.

‍

Rheological Superiority

Polynucleotides do not simply coexist within the gel; they fundamentally alter its rheological profile.

• Viscosity and Elasticity: PROSCULPT demonstrates an optimised balance of viscosity (G’) and elasticity (G”), enabling robust lift while maintaining flexibility and natural rebound.
• Injection Dynamics: PN-induced bonding within the HA matrix eliminates free HA separation, creating a monophasic gel with smooth, predictable extrusion. Injection force is markedly reduced (10.12 N), providing superior control and tactile feedback to the injector.
• Clinical Handling: Practitioners experience the precision of a biphasic gel with the cohesiveness of a monophasic filler — an unprecedented combination that enhances both handling and patient outcomes.

‍

Longevity Through Polynucleotide Stabilisation

Conventional Hyaluronic Acid fillers are subject to enzymatic degradation, limiting their duration of effect. Polynucleotides act as structural stabilisers, shielding HA chains and improving gel cohesion.

Preclinical studies demonstrate that PRODERMIS PROSCULPT maintains volume for up to 56 weeks, compared with 44 weeks for HA-only controls. This extended persistence reduces treatment frequency and enhances patient satisfaction while preserving predictable resorption over time.

‍

Biological Benefits Beyond Volume

The regenerative profile of Polynucleotides delivers measurable improvements in dermal health:

• Collagen stimulation enhances firmness and elasticity.
• Anti-inflammatory modulation supports faster recovery and reduced post-procedural reactivity.
• Improved tissue microenvironment promotes integration and natural blending with surrounding structures.

Thus, PROSCULPT functions simultaneously as a filler and a regenerative agent — offering volumisation, integration, and progressive biorepair within a single syringe.

‍

Clinical Implications

For aesthetic practitioners, PRODERMIS PROSCULPT provides:

• A dual-action treatment addressing both immediate structural correction and long-term dermal quality.
• A predictable and comfortable injection experience, with reduced extrusion force and stable gel behaviour.
• Extended clinical durability, lowering retreatment frequency and improving patient retention.
• A differentiated therapeutic profile compared with conventional fillers, positioning it as a next-generation option in advanced aesthetic protocols.

‍

Conclusion

PRODERMIS PROSCULPT is not merely an incremental improvement on existing filler technology. By integrating cross-linked Hyaluronic Acid with Polynucleotides, it achieves a unique combination of structural volumisation, regenerative bioactivity, rheological optimisation, and extended longevity.

For physicians, this represents a new class of dermal filler: one that moves beyond volumisation alone to deliver true tissue transformation.

‍

‍

‍

‍